Table 3. Clinical, demographic, and allele distribution of the sample.

	Placebo (n=45)	Escitalopram (n=75)	tDCS (n=75)	p-value
Clinical characteristics
Female	31 (68.9)	52 (70.3)	49 (66.2)	0.86
Age, mean (SD)	41.8 (13.1)	41.5 (12.5)	45.2 (11.8)	0.15
Years of schooling	15.7 (3.45)	14.5 (4.1)	15.7 (5.2)	0.24
White ethnicity (self-declared)	10 (22.2)	19 (25.3)	25 (33.3)	0.35
Body mass index, mean (SD)	27.2 (6)	26.3 (5)	25.7 (4.8)	0.31
Depression
Baseline HDRS-17, mean (SD)	22.5 (4.1)	21.8 (3.6)	21.6 (4.1)	0.44
Endpoint HDRS-17, mean (SD)	16.5 (8.3)	10.3 (5.9)	13.1 (6.6)	< 0.001
Response rate	11 (24.4)	38 (50.7)	30 (40)	0.02
Treatment-resistant depression	15 (33.3)	19 (25.3)	26 (34.7)	0.42
SNPs
BDNF, Met-carriers	17 (37.8)	27 (36)	24 (32)	0.78
BDNF, Val/Val	28 (62.2)	48 (64)	51 (68)
SLC6A4, short allele carriers	31 (68.9)	45 (60)	53 (70.7)	0.35
SLC6A4, long/long	14 (31.1)	30 (40)	22 (29.3)
TPH1, T-carriers	32 (71.1)	47 (62.7)	42 (56)	0.25
TPH1, C/C	13 (28.9)	28 (37.3)	33 (44)
COMT, G-carriers	14 (31.1)	24 (33.3)	58 (77.3)	0.32
COMT, A/A	31 (68.9)	50 (66.7)	17 (22.7)
HTR2A (rs6311), T-carriers	28 (62.2)	57 (76)	46 (61.3)	0.11
HTR2A (rs6311), C/C	17 (37.8)	18 (24)	29 (38.7)
HTR2A (rs6313), A-carriers	28 (62.2)	58 (77.3)	46 (61.3)	0.07
HTR2A (rs6313), G/G	17 (37.8)	17 (22.7)	29 (38.7)
HTR2A (rs7997012), A-carriers	26 (57.8)	35 (46.7)	37 (49.3)	0.49
HTR2A (rs7997012), G/G	19 (42.2)	40 (53.3)	38 (50.7)

Data presented as n (%), unless otherwise specified.

BDNF = brain-derived neurotrophic factor; COMT = catechol-o-methyltransferase; HDRS = Hamilton Depression Rating Scale; SD = standard deviation; SLC6A4 = solute carrier family 6, member 4; tDCS = transcranial direct current stimulation; TPH1 = tryptophan hydroxylase 1.